MA43833B1 - Nouvelle forme cristalline de sel de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine - Google Patents
Nouvelle forme cristalline de sel de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamineInfo
- Publication number
- MA43833B1 MA43833B1 MA43833A MA43833A MA43833B1 MA 43833 B1 MA43833 B1 MA 43833B1 MA 43833 A MA43833 A MA 43833A MA 43833 A MA43833 A MA 43833A MA 43833 B1 MA43833 B1 MA 43833B1
- Authority
- MA
- Morocco
- Prior art keywords
- crystalline form
- pyrrol
- difluorophenyl
- fluorophenyl
- sulfonyl
- Prior art date
Links
- OUNXGNDVWVPCOL-UHFFFAOYSA-N 1-[5-(2,4-difluorophenyl)-1-(3-fluorophenyl)sulfonyl-4-methoxypyrrol-3-yl]-N-methylmethanamine Chemical class FC1=C(C=CC(=C1)F)C1=C(C(=CN1S(=O)(=O)C1=CC(=CC=C1)F)CNC)OC OUNXGNDVWVPCOL-UHFFFAOYSA-N 0.000 title 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- -1 (2,4-difluorophenyl) -1 - ((3-fluorophenyl) sulfonyl) -4-methoxy-1h-pyrrol-3-yl Chemical group 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
La présente invention décrit une nouvelle forme cristalline i de chlorhydrate, une forme cristalline ii de chlorhydrate, une forme cristalline de succinate, une forme cristalline de tartrate, une forme cristalline i de fumarate et une forme cristalline ii de fumarate de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine. Les nouvelles formes cristallines ci-dessus décrites présentent une solubilité élevée dans l'eau et une excellente stabilité sous des conditions de résistance à l'humidité et des conditions d'exposition à une humidité élevée, et peuvent donc être pharmaceutiquement employées.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160036080A KR102081920B1 (ko) | 2016-03-25 | 2016-03-25 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| PCT/KR2017/002914 WO2017164576A1 (fr) | 2016-03-25 | 2017-03-17 | Nouvelle forme cristalline de sel de 1-(5-(2,4-difluorophényl)-l-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43833B1 true MA43833B1 (fr) | 2020-08-31 |
Family
ID=59900401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43833A MA43833B1 (fr) | 2016-03-25 | 2017-03-17 | Nouvelle forme cristalline de sel de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US10336695B2 (fr) |
| EP (1) | EP3433233B1 (fr) |
| JP (1) | JP6554617B2 (fr) |
| KR (1) | KR102081920B1 (fr) |
| CN (1) | CN108602772B (fr) |
| AR (1) | AR107963A1 (fr) |
| AU (1) | AU2017238918B2 (fr) |
| BR (1) | BR112018069461A2 (fr) |
| CA (1) | CA3014745C (fr) |
| CL (3) | CL2018002416A1 (fr) |
| CO (1) | CO2018008833A2 (fr) |
| DO (1) | DOP2018000190A (fr) |
| EA (1) | EA029995B1 (fr) |
| ES (1) | ES2818902T3 (fr) |
| HR (1) | HRP20201594T1 (fr) |
| HU (1) | HUE053502T2 (fr) |
| JO (1) | JOP20170070B1 (fr) |
| MA (1) | MA43833B1 (fr) |
| MX (1) | MX382701B (fr) |
| MY (1) | MY196299A (fr) |
| NZ (1) | NZ745266A (fr) |
| PE (1) | PE20190170A1 (fr) |
| PH (1) | PH12018501846A1 (fr) |
| PL (1) | PL3433233T3 (fr) |
| PT (1) | PT3433233T (fr) |
| RS (1) | RS60884B1 (fr) |
| SG (1) | SG11201806966SA (fr) |
| SI (1) | SI3433233T1 (fr) |
| TN (1) | TN2018000288A1 (fr) |
| TW (1) | TWI626234B (fr) |
| WO (1) | WO2017164576A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102081920B1 (ko) | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| KR102233456B1 (ko) | 2017-05-31 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102233455B1 (ko) * | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102126576B1 (ko) | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
| KR102570011B1 (ko) * | 2019-12-18 | 2023-08-23 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루우로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물 |
| CR20230266A (es) * | 2020-12-18 | 2023-07-19 | Daewoong Pharmaceutical Co Ltd | Nueva formulación para administración oral, que comprende 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina |
| TWI892291B (zh) * | 2021-05-26 | 2025-08-01 | 南韓商大熊製藥股份有限公司 | 含有1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之液體醫藥組成物之醫藥容器 |
| CN117820193A (zh) * | 2022-09-29 | 2024-04-05 | 安徽皓元药业有限公司 | 一种非苏拉赞盐酸盐晶型a及其制备方法 |
| KR20250014615A (ko) * | 2023-07-21 | 2025-02-03 | 한림제약(주) | 보노프라잔 푸마르산염의 제조방법 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101178747B1 (ko) * | 2004-09-30 | 2012-09-03 | 다케다 야쿠힌 고교 가부시키가이샤 | 프로톤 펌프 저해제 |
| HRP20110473T1 (hr) | 2005-08-30 | 2011-07-31 | Takeda Pharmaceutical Company Limited | Supstituirani derivati 1-heterociklilsulfonil, 2-aminometil, 5-(hetero)-aril 1-h-pirola kao inhibitori kiselinske sekrecije |
| US7994205B2 (en) * | 2006-03-31 | 2011-08-09 | Takeda Pharmaceutical Company Limited | Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors |
| US20100113524A1 (en) * | 2006-09-19 | 2010-05-06 | Garst Michael E | Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety |
| US8933105B2 (en) * | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| JP6292736B2 (ja) * | 2012-11-19 | 2018-03-14 | ジエンス ハンセン ファーマセウティカル カンパニー リミテッド | ピロールスルホンアミド誘導体、その製造法およびその医療用途 |
| KR102084185B1 (ko) * | 2013-08-29 | 2020-03-04 | 주식회사 대웅제약 | 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법 |
| CN104447491B (zh) | 2014-11-19 | 2017-06-23 | 连云港恒运医药有限公司 | 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途 |
| CN106957252B (zh) * | 2014-11-19 | 2019-11-19 | 连云港恒运药业有限公司 | 一种质子泵抑制剂中间体及其制备方法 |
| KR101613245B1 (ko) * | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| KR20170113040A (ko) | 2016-03-25 | 2017-10-12 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
| KR102081920B1 (ko) | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| KR102233456B1 (ko) | 2017-05-31 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102233455B1 (ko) | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102126576B1 (ko) | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
-
2016
- 2016-03-25 KR KR1020160036080A patent/KR102081920B1/ko active Active
-
2017
- 2017-03-17 PT PT177705464T patent/PT3433233T/pt unknown
- 2017-03-17 PE PE2018001574A patent/PE20190170A1/es unknown
- 2017-03-17 RS RS20201203A patent/RS60884B1/sr unknown
- 2017-03-17 SG SG11201806966SA patent/SG11201806966SA/en unknown
- 2017-03-17 EP EP17770546.4A patent/EP3433233B1/fr active Active
- 2017-03-17 MY MYPI2018703342A patent/MY196299A/en unknown
- 2017-03-17 ES ES17770546T patent/ES2818902T3/es active Active
- 2017-03-17 MA MA43833A patent/MA43833B1/fr unknown
- 2017-03-17 CA CA3014745A patent/CA3014745C/fr active Active
- 2017-03-17 NZ NZ745266A patent/NZ745266A/en unknown
- 2017-03-17 WO PCT/KR2017/002914 patent/WO2017164576A1/fr not_active Ceased
- 2017-03-17 MX MX2018009219A patent/MX382701B/es unknown
- 2017-03-17 SI SI201730397T patent/SI3433233T1/sl unknown
- 2017-03-17 TN TNP/2018/000288A patent/TN2018000288A1/en unknown
- 2017-03-17 CN CN201780008736.5A patent/CN108602772B/zh active Active
- 2017-03-17 US US16/073,359 patent/US10336695B2/en active Active
- 2017-03-17 BR BR112018069461-4A patent/BR112018069461A2/pt not_active Application Discontinuation
- 2017-03-17 PL PL17770546T patent/PL3433233T3/pl unknown
- 2017-03-17 JP JP2018549562A patent/JP6554617B2/ja active Active
- 2017-03-17 HR HRP20201594TT patent/HRP20201594T1/hr unknown
- 2017-03-17 AU AU2017238918A patent/AU2017238918B2/en active Active
- 2017-03-17 HU HUE17770546A patent/HUE053502T2/hu unknown
- 2017-03-21 TW TW106109339A patent/TWI626234B/zh active
- 2017-03-22 JO JOP/2017/0070A patent/JOP20170070B1/ar active
- 2017-03-23 EA EA201790454A patent/EA029995B1/ru not_active IP Right Cessation
- 2017-03-23 AR ARP170100726A patent/AR107963A1/es unknown
-
2018
- 2018-08-23 CL CL2018002416A patent/CL2018002416A1/es unknown
- 2018-08-24 CO CONC2018/0008833A patent/CO2018008833A2/es unknown
- 2018-08-30 PH PH12018501846A patent/PH12018501846A1/en unknown
- 2018-08-31 DO DO2018000190A patent/DOP2018000190A/es unknown
-
2019
- 2019-05-14 US US16/411,270 patent/US10683268B2/en active Active
- 2019-12-18 US US16/718,300 patent/US10889545B2/en active Active
- 2019-12-18 US US16/718,286 patent/US10913715B2/en active Active
-
2020
- 2020-01-22 CL CL2020000186A patent/CL2020000186A1/es unknown
- 2020-07-08 CL CL2020001826A patent/CL2020001826A1/es unknown
-
2021
- 2021-01-19 US US17/151,901 patent/US11459297B2/en active Active
-
2022
- 2022-07-27 US US17/874,700 patent/US11858894B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43833B1 (fr) | Nouvelle forme cristalline de sel de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine | |
| JOP20200194A1 (ar) | صور بلورية جديدة | |
| PE20170189A1 (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| HRP20241768T1 (hr) | Heterociklički spoj | |
| PE20220569A1 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y metodos de tratamiento con dichos compuestos | |
| PE20191108A1 (es) | Inhibidores selectivos de jak1 | |
| EP2178869A4 (fr) | Composés d'indole en tant qu'inhibiteurs de nécrose cellulaire | |
| PE20120812A1 (es) | Compuestos vinil indazolilo | |
| MA32563B1 (fr) | Dabigatran pour cathétérisme cardiaque de chirurgie percutanée | |
| MX2010006260A (es) | Composiciones orales de abt-263 para tratar cancer. | |
| PE20081596A1 (es) | Derivados fluorinados de deferiprona | |
| PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| EA202191833A1 (ru) | Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида | |
| MX2019002396A (es) | Composiciones oftalmicas. | |
| MX2021010133A (es) | Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifl uorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carbox amida monohidratada. | |
| IL283823A (en) | 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease | |
| ECSP20066271A (es) | Derivados de pirazo-tetrahidroisoquinolina como moduladores positivos del receptor de dopamina d1 | |
| PE20081495A1 (es) | Derivados 4,5-difenilpirrol-2-carboxamida como antagonistas de los receptores cb1 | |
| PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
| PE20091617A1 (es) | Tiazolil-dihidro-indazoles | |
| MX2020002505A (es) | Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso. | |
| PH12022551415A1 (en) | Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine | |
| WO2018035459A8 (fr) | Composition pharmaceutique et procédés d'utilisation | |
| PE20081254A1 (es) | Derivados de 5-alquiloxi-indolin-2-ona, su preparacion y sus aplicaciones en terapeutica | |
| EA202091737A1 (ru) | Производные индола и бензимидазола в качестве двойных антагонистов рецепторов 5-ht2a и 5-ht6 |